We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

77 hedge funds and large institutions have $195M invested in Adaptimmune Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more call options, than puts

Call options by funds: $219K | Put options by funds: $70K

0.44% more ownership

Funds ownership: 11.75% → 12.19% (+0.44%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 80 → 77 (-3)

15% less capital invested

Capital invested by funds: $229M → $195M (-$34.2M)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

30% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 23

Holders
77
Holders Change
-3
Holders Change %
-3.75%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
16
Reduced
23
Closed
15
Calls
$219K
Puts
$70K
Net Calls
+$149K
Net Calls Change
+$257K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$11.6M
2
Bank of America
Bank of America
North Carolina
+$803K
3
ECM
ExodusPoint Capital Management
New York
+$515K
4
Barclays
Barclays
United Kingdom
+$434K
5
LFCM
Long Focus Capital Management
Puerto Rico
+$429K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.28M
2
Renaissance Technologies
Renaissance Technologies
New York
-$772K
3
ECM
Endurant Capital Management
California
-$579K
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$548K
5
Two Sigma Investments
Two Sigma Investments
New York
-$544K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
51
Acadian Asset Management
Massachusetts
$23K -$52.6K -30,620 -69%
Simplex Trading
52
Simplex Trading
Illinois
$23K +$15.7K +9,145 +207%
ProShare Advisors
53
ProShare Advisors
Maryland
$18K -$5.98K -3,479 -24%
RJA
54
Raymond James & Associates
Florida
$18K – – –
RPCA
55
Running Point Capital Advisors
California
$17K – – –
IUHSA
56
Itau Unibanco Holding S.A.
Brazil
$13K -$9.71K -5,653 -43%
VRM
57
Vectors Research Management
New York
$12K +$12K +7,000 New
Wells Fargo
58
Wells Fargo
California
$10K -$2.74K -1,596 -20%
UBS Group
59
UBS Group
Switzerland
$8K -$1.35K -788 -14%
CAPTRUST Financial Advisors
60
CAPTRUST Financial Advisors
North Carolina
$8K – – –
CSS
61
Cubist Systematic Strategies
Connecticut
$4K -$72.3K -42,106 -95%
BNP Paribas Financial Markets
62
BNP Paribas Financial Markets
France
$3.56K +$3.59K +2,092 New
QT
63
Quantbot Technologies
New York
$3K – – –
Rockefeller Capital Management
64
Rockefeller Capital Management
New York
$3K – – –
US Bancorp
65
US Bancorp
Minnesota
$2K -$16.1K -9,367 -89%
Osaic Holdings
66
Osaic Holdings
Arizona
$2K – – –
S
67
SignatureFD
Georgia
$1K -$610 -355 -31%
BBPWM
68
Blue Bell Private Wealth Management
Pennsylvania
$1K – – –
CHA
69
Carmichael Hill & Associates
Maryland
$1K – – –
CA
70
Clearstead Advisors
Ohio
$1K – – –
JPLA
71
Joseph P. Lucia & Associates
New York
$1K – – –
WAM
72
Worth Asset Management
Texas
$1K – – –
LC
73
Lindbrook Capital
California
$1K +$239 +139 +78%
ED
74
Exane Derivatives
France
$206 – – –
Two Sigma Investments
75
Two Sigma Investments
New York
– -$544K -263,960 Closed
1 2
3
4

ADAP Hedge Fund Activity: Q2 2022 in Review

77 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2022, worth a combined $195M — down 15% from $229M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ADAP and 12 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 16 added.

The largest buyer was PFM Health Sciences, adding an estimated $11.6M. The largest seller was Millennium Management, cutting an estimated $2.28M.

  • 77 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2022, down from 80 in Q1 2022.
  • Funds reported $195M of Adaptimmune Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
  • 12 funds opened new Adaptimmune Therapeutics positions in Q2 2022 and 15 closed out, a net change of -3 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $11.6M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2022 was Millennium Management, an estimated $2.28M sold.

Based on aggregated 13F filings for Q2 2022.